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| INTRODUCTION
Despite advances in the treatment and management of multiple myeloma (MM) over the past 15 years, relapsed and/or refractory MM remains a common and life-threatening diagnosis. 1, 2 Optimal therapy given at first relapse of MM is important for achieving maximal treatment response and prolonged survival. [3] [4] [5] Compared with subsequent relapses, the disease at first relapse is more sensitive to treatment, as there are fewer genetic alterations conferring drug resistance. 6 Consistent with this, overall response rates (ORRs) and duration of response have been found to progressively decline with each successive relapse. 6, 7 In addition, a substantial portion of patients with relapsed MM may not receive treatment beyond second-line therapy due to death or other reasons, suggesting that for some patients with relapsed disease, the first relapse may be the only opportunity to receive optimal therapy. 8 Overall, these considerations underscore the importance of early administration of effective therapies to achieve deep responses at first relapse.
Carfilzomib is an irreversible and specific second-generation proteasome inhibitor used for the treatment of relapsed or refractory MM (RRMM). In the randomized, phase 3 ASPIRE study, triplet therapy with carfilzomib (given twice weekly on two consecutive days as an intrave- To improve convenience and lessen the burden on patients and the healthcare system, a less-frequent once-weekly carfilzomib dosing schedule has been investigated. In previous studies, once-weekly carfilzomib with dexamethasone has been found to be an effective and well-tolerated regimen for patients with RRMM. 11, 12 Given the established efficacy of twice-weekly KRd in RRMM, and the potential for improved convenience with once-weekly carfilzomib dosing, we initiated a phase 1b study exploring once-weekly KRd in patients with RRMM and newly diagnosed MM (NDMM). The primary objective of the study was assessment of the safety and tolerability of once-weekly KRd; efficacy was a secondary endpoint.
| METHODS

| Study design and participants
This was an open-label, multicenter, phase 1b, dose-finding study of IV hydration (250-500 mL normal saline or appropriate IV fluid) was administered before each carfilzomib infusion during cycle one. Patients received antiviral prophylaxis with valacyclovir and venous thromboembolic prophylaxis with aspirin (or other anticoagulant or antiplatelet medication).
Patients at high risk for tumor lysis syndrome received allopurinol (or other approved uric acid-lowering agent) at the investigator's discretion.
| Assessments
The primary objective was to assess the safety and tolerability of onceweekly KRd. The clinical activity (efficacy) of once-weekly KRd was assessed as a secondary objective. Safety and efficacy analyses were based upon the safety population, defined as patients who had received at least one dose of study drug, and performed by dosing level of carfilzomib.
Safety and tolerability were evaluated according to the type, incidence, Patients with normal cytogenetics or other chromosomal abnormalities were included in the standard-risk group.
| Data sharing
Qualified researchers may request data from Amgen clinical studies.
Complete details are available at the following: http://www.amgen.
com/datasharing. Across the dose-evaluation and dose-expansion portions of the study, the median age of patients with RRMM was 68.5 years (range, At least one TEAE occurred in all patients. The patient incidence of the most common TEAEs is shown in Table 2 . (Table 3) .
Among all patients (n = 56), the ORR was 89.3%, the ≥VGPR rate was 69.6%, and the ≥CR rate was 28.6%. dexamethasone. 17, 18 In a phase one study of pomalidomide, bortezomib, and dexamethasone in lenalidomide-refractory and proteasome inhibitorexposed relapsed or relapsed and refractory MM patients (n = 34), one patient died in cycle three due to cardiac arrest. 19 In this study, once-weekly KRd had acceptable toxicity. 8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46 F I G U R E 1 Swimmers plots for exposure to carfilzomib in the (A) 56-mg/m 2 group and (B) 70-mg/m in an intention-to-treat analysis. These ORRs are comparable to the ORR of 87.1% previously reported for twice-weekly KRd in the ASPIRE study. 10 The rate of CR or better among all patients enrolled in the study was (it should be noted that length of treatment exposure differed between studies). 10 In a previous study of once-weekly KRd (with carfilzomib 56 mg/m 2 ) conducted in patients with early relapsed and refractory MM (n = 28; median of 1 prior line of therapy), the ≥VGPR rate was 75% and the ≥CR rate was 36%. 20 The 26-month projected PFS and OS rates were 63% and 85%, respectively. Note: Adverse events (AEs) reported as preferred term. Neutropenia included both neutropenia and neutrophil count decreased preferred terms; thrombocytopenia included both thrombocytopenia and platelet count decreased preferred terms. 
T A B L E 3 Response as determined by investigators
